Drugs / Pethidin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06111872 Comparator | Jul 2023 → Feb 2024 | bile duct cyst, cholangitis, choledocholithiasis, malignant pancreatic neoplasm | National University of Malaysia | Completed | No outcome recorded |
| Phase 4 | NCT06513806 Comparator | Aug → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pethidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06111872 ↗ |
| Known as | pethidine | “Pethidine inhibits norepinephrine.” NCT06513806 ↗ |
| Action | Inhibit | “Pethidine inhibits norepinephrine” NCT06513806 ↗ |
| Route | Intravenous | “Initial IV Midazolam 0.05mg/kg given over 1 minute with IV Pethidine 0.7mcg/kg.” NCT06111872 ↗ |